Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of anti-CD3-EGFR bispecific antibody-labeled DC-CIK immune cells on proliferation of lung cancer cells

Minjie Li , Yuan Zhong

Department of Thoracic Surgery, Zhongshan Hospital Xiamen University, Xiamen 361004, Fujian Province, China;

For correspondence:- Minjie Li Email: michael4523@126.com

Accepted: 5 May 2024 Published: 29 May 2024

Citation: Li M, Zhong Y. Effect of anti-CD3-EGFR bispecific antibody-labeled DC-CIK immune cells on proliferation of lung cancer cells. Trop J Pharm Res 2024; 23(5):809-813 doi: 10.4314/tjpr.v23i5.2

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of DC-CIK immune cells labeled with anti-CD3-EGFR bispecific antibody (BSAB) on the proliferation of lung cancer (LC) cells in order to generate data useful for enhancing the therapy of LC.

Methods: The anti-CD3 and anti-EGFR monoclonal antibodies were labeled on the surface of DC-CIK cells using chemical coupling method. Successful preparation of anti-CD3-EGFR BSAB was determined using SDS-PAGE. Two groups of cells were used: labeled group and a DC-CIK group. The cytotoxic effect on A549 LC cells was determined in vitro, and the tumor inhibition capacity was determined in 30 nude mice with LC.

Results: The killing rate of EGFR-positive A549 cells in labeled group was more severe than the killing rate in DC-CIK cells (p < 0.05). Cellular growth rate was significantly lesser in labelled A549 LC cells than in DC-CIK group. After 2 months of treatment, nude mouse tumor size in labeled group was smaller than the tumor volume in DC-CIK group. No obvious adverse reactions (ARs) were observed in both groups.

Conclusion: In vitro, CD3-EGFR BSAB-labeled DC-CIK immune cells produce cytotoxic effect and inhibit the proliferation of LC cells, while in vivo studies reveal that the cells produce good therapeutic effect on LC.

Keywords: Anti-CD3-EGFR BSAB, DC-CIK cells, Lung cancer, Proliferation, Killing effect